Clinical Trial Outcomes Risk: Failure of deucrictibant or any future product candidates to achieve positive results in ongoing or future clinical trials could significantly harm the company's prospects.

Regulatory Approval Risk: Even with successful clinical trial data, there is no guarantee that regulatory authorities like the FDA or EMA will grant marketing approval for deucrictibant or other product candidates.

Competition Risk: Pharvaris operates in a highly competitive market for hereditary angioedema (HAE) treatments, facing established therapies and other pipeline candidates, which could limit market share.